Ocugen (OCGN) – Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market


Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

 

MALVERN, Pa., April 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 10 million shares of its common stock at a purchase price of $10 per share in a registered direct offering. The offering is expected to close on or about April 27, 2021, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds of the offering are expected to be approximately $100 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses.

The shares of common stock described above are being offered pursuant to an automatic “shelf” registration statement (File No. 333-254550) filed with the Securities and Exchange Commission (“SEC”) on March 22, 2021 which automatically became effective pursuant to SEC rules. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: [email protected] or by telephone: (646) 975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Corporate Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corporate Development
[email protected]

Media Contact:
LaVoieHealthScience
Emmie Twombly
[email protected]
+1 857-389-6042

Release – Ocugen (OCGN) – Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market


Ocugen Inc. Announces $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

 

MALVERN, Pa., April 23, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 10 million shares of its common stock at a purchase price of $10 per share in a registered direct offering. The offering is expected to close on or about April 27, 2021, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds of the offering are expected to be approximately $100 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses.

The shares of common stock described above are being offered pursuant to an automatic “shelf” registration statement (File No. 333-254550) filed with the Securities and Exchange Commission (“SEC”) on March 22, 2021 which automatically became effective pursuant to SEC rules. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: [email protected] or by telephone: (646) 975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Corporate Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corporate Development
[email protected]

Media Contact:
LaVoieHealthScience
Emmie Twombly
[email protected]
+1 857-389-6042

Release – Energy Fuels (UUUU)(EFR:CA) – Awarded Additional $1.75 Million by U.S. Department of Energy for Rare Earth Feasibility Study

 

 


Energy Fuels and Team from Penn State University Awarded Additional $1.75 Million by U.S. Department of Energy for Rare Earth Feasibility Study

 

LAKEWOOD, Colo.April 23, 2021 /CNW/ – Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) (“Energy Fuels” or the “Company”) is pleased to announce that the U.S. Department of Energy (“DOE“) Office of Fossil Energy and National Energy Technology Laboratory has exercised their option to award Energy Fuels, working with a team from Penn State University, an additional $1.75 million to complete a feasibility study (“Feasibility Study“) on the production of rare earth element (“REE“) products from natural coal-based resources, as well as from other materials such as REE-containing ores like the natural monazite ore (“Monazite“) the Company is currently processing at its White Mesa Mill in Utah.

This award follows the DOE providing Energy Fuels a $150,000 contract in 2020 for the successful completion of a conceptual design for the same initiative, resulting in a total award to Energy Fuels of $1.9 million. The Feasibility Study is intended to support a cost estimate for the production of individually separated rare earth oxides and rare earth metals and alloys from coal-based resources or other resources, including Monazite, within the U.S., with a focus on REEs for the production of commodity and defense-related products.

Energy Fuels is already evaluating the potential to develop commercial REE separation, metals, alloys, and other downstream REE capabilities at the White Mesa Mill, or nearby, with the goal of fully integrating a commercial U.S. REE supply chain in the coming years. The Company’s work on the DOE Feasibility Study is expected to complement these efforts and has the potential to accelerate the Company’s move into commercial production of separated REE oxides and other value-added REE products in the U.S. in the coming years.

“We are pleased to continue our collaboration with the U.S. Department of Energy, as we work together to restore critical U.S. rare earth supply chains available for domestic manufacturing,” stated Mark S. Chalmers, President and CEO of Energy Fuels. “As we continue to ramp-up production of an intermediate rare earth product at the White Mesa Mill in Utah, we are moving forward with designing and developing the infrastructure needed to responsibly produce separated rare earth oxides and other products needed by the electric vehicle, renewable energy, defense and other domestic industries. Furthermore, we believe we can design our infrastructure to process feeds produced in the DOE program as well as the Monazite we are currently processing, for the recovery of uranium and REE products. We believe these kinds of collaborative public-private partnerships will be a key to restoring U.S. global leadership in the clean energy sector and re-establishing critical defense-related supply chains.”

About Energy Fuels: Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The Company also produces vanadium from certain of its projects, as market conditions warrant, and is in the process of ramping-up to commercial production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR“) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com. 

Cautionary Note Regarding Forward-Looking Statements: This news release contains “forward-looking information” within the meaning of applicable securities laws in the United States and Canada. Forward-looking information may relate to future events or future performance of Energy Fuels. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation as to the outcome of the Feasibility Study; any expectation that the White Mesa Mill will be successful in producing REE carbonate on a commercial basis; any expectation that Energy Fuels will be successful in developing U.S. separation, metals or metal/alloy capabilities at the White Mesa Mill or nearby, or otherwise fully integrating a low cost U.S REE supply chain in the future; any expectation with regard to the cost of producing and separating REE carbonate at the White Mesa Mill; any expectation that the Company’s work on the Feasibility Study will complement the Company’s current efforts or have the potential to accelerate the Company’s move into commercial production of separated REE oxides and other value-added REE products; any expectation that the Company’s collaboration with DOE will restore critical U.S. rare earth supply chains available for domestic manufacturing; any expectation that the Company can design its infrastructure to process feeds produced in the DOE program as well as the Monazite it is currently processing, for the recovery of uranium and REE products; and any expectation that the Company’s collaboration with DOE will be a key to restoring U.S. global leadership in the clean energy sector and re-establishing critical defense-related supply chains. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: technical difficulties; processing difficulties and upsets; commodity price levels and fluctuations; competition from other facilities domestically and internationally; available supplies of coal-based or other resources that meet commercial specifications; the availability of long-term purchase and supply agreements; capital requirements; the ability of the White Mesa Mill to produce REE carbonate or other REE products that meet commercial specifications on a commercial scale at acceptable costs; market factors, including future demand for REEs; permitting and licensing matters; and legal and regulatory challenges. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels assumes no obligation to update the information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.

For further information: Investor Inquiries: Energy Fuels Inc., Curtis Moore, VP – Marketing and Corporate Development, (303) 974-2140, or Toll free: (888) 864-2125, [email protected], www.energyfuels.com

Release – CoreCivic (CXW) – Announces 2021 First Quarter Earnings Release and Conference Call Dates


CoreCivic Announces 2021 First Quarter Earnings Release and Conference Call Dates

 

BRENTWOOD, Tenn., April 23, 2021 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (the Company) announced today that it will release its 2021 first quarter financial results after the market closes on Wednesday, May 5, 2021.  

A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, May 6, 2021, and will be accessible through the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. The live broadcast can also be accessed by dialing 800-367-2403 in the U.S. and Canada, including the confirmation passcode 7487376. An online replay of the call will be archived on our website promptly following the conference call. In addition, there will be a telephonic replay available beginning at 1:00 p.m. central time (2:00 p.m. eastern time) on May 6, 2021, through 1:00 p.m. central time (2:00 p.m. eastern time) on May 14, 2021. To access the telephonic replay, dial 888-203-1112 in the U.S. and Canada. International callers may dial +1 719-457-0820 and enter passcode 8097453.

About CoreCivic

CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that serve the public good through corrections and detention management, a network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believes it is the largest private owner of real estate used by government agencies in the U.S. CoreCivic has been a flexible and dependable partner for government for more than 35 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. 

Contact:    Investors: Cameron Hopewell – Managing Director, Investor Relations – (615) 263-3024
    Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – Avivagen (VIVXF)(VIV:CA) – Announces Largest Single Customer Purchase Order


Avivagen Announces Largest Single Customer Purchase Order

 

 4 tonne order is the largest single shipment purchase in Avivagen’s history
 Purchase order represents more than 40% of previous fiscal year’s total volume

Ottawa, ON / Business Wire/ April 23, 2021 / – Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce it has received a purchase order for a single shipment of 4.4 metric tonnes of OxC-beta™ Livestock from UNAHCO. The purchase order is the largest single shipment purchase order of OxC-beta™ to date and represents a 10% increase in size over its previous record single shipment order.

“UNAHCO has been amongst the earliest adopters of OxC-beta™ for use in swine, and recently poultry, and its continued growth in order frequency and size is a clear indicator of the value that our product brings to the livestock feed production market,” said Kym Anthony, Chief Executive Officer, Avivagen Inc.  “We continue to add new applications and markets for OxC-beta™ worldwide that, taken together with our ongoing relationships with great and growing customers like UNAHCO, are providing dramatic growth potential and success for Avivagen. We also want to thank our colleagues who worked with the government in the Philippines to get this order cleared during challenging COVID-19 restrictions.”

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim”, anticipate”, appear”, believe”, consider”, could”, estimate”, expect”, if”, intend”, goal”, hope”, likely”, may”, plan”, possibly”, potentially”, pursue”, seem”, should”, whether”, will”, would” and similar expressions. Statements set out in this news release relating to the future delivery of product based on the purchase order received, Avivagen’s expectations as to growth of its branding in certain jurisdictions, continued distribution and acceptance of Avivagen’s technology, anticipated growth in demand for Avivagen’s products,  the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the order described may not result in new orders for Avivagens products,  the customer plans may change due to many reasons Avivagens products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds,  and fulfillment of the order may be delayed beyond current expectation, or in the worst case cancelled, in each case due to many factors, many of which are outside of Avivagens control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagens most recent managements discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.

Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: [email protected]

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

Indonesia Energy Corp (INDO) – INDO Begins Drilling

Friday, April 23, 2021

Indonesia Energy Corp (INDO)
INDO Begins Drilling

Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. It holds two oil and gas assets through its subsidiaries in Indonesia: one producing block (the Kruh Block) and one exploration block (the Citarum Block). The Kruh Block is located to the northwest of Pendopo, Pali, South Sumatra. The Citarum Block is located to the south of Jakarta.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    INDO begins drilling in the Kruh Block. Well Kruh-25 is the first of three back-to-back wells. Management expects to drill 5 wells in 2021, 6 in 2022, and 7 in 2023. Other details regarding drilling depth, time to drill, and expected initial production were unchanged. The announcement has been long awaited, with the estimated start date being pushed back several times.

    Drilling had been delayed by COVID and regulatory approval.  INDO initially planned to drill 6 Kruh wells in 2020 with the first well beginning shortly after renewing an operating agreement in May 2020. In July 2020, management pushed back first well expectations to September 2020. In September, it pushed back expectations to “one well in 2020”. In December, management cited a January 2021 start …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Travelzoo (TZOO) – Reports First Quarter 2021 Results

 

 


Travelzoo Reports First Quarter 2021 Results

 

NEW YORK
April 22, 2021 (GLOBE NEWSWIRE) — Travelzoo® (NASDAQ: TZOO):

  • Consolidated revenue of 
    $14.3 million, down 30% year-over-year and up 14% quarter-over-quarter
  • Non-GAAP consolidated operating profit of 
    $0.6 million
  • Earnings per share (EPS) of (
    $0.14) attributable to 
    Travelzoo from continuing operations
  • Cash flow from operations of 
    $11.9 million

Travelzoo, a global Internet media company that publishes exclusive offers and experiences for members, today announced financial results for the first quarter ended 
March 31, 2021. Consolidated revenue was 
$14.3 million, down 30% from 
$20.3 million year-over-year and up 14% from 
$12.5 million in the prior quarter. Reported revenue excludes revenue from discontinued operations in 
Asia Pacific
Travelzoo’s reported revenue consists of advertising revenues and commissions, derived from and generated in connection with purchases made by 
Travelzoo members.

The reported net loss attributable to 
Travelzoo from continuing operations was 
$1.6 million for Q1 2021. At the consolidated level, including minority interests, the reported net loss from continuing operations was 
$1.7 million. EPS from continuing operations was (
$0.14), compared to (
$0.32) in the prior-year period.

Non-GAAP operating profit was 
$0.6 million. The calculation of non-GAAP operating profit excludes amortization of intangibles (
$0.3 million), stock option expenses (
$0.9 million), and severance-related expenses (
$0.2 million). See section “Non-GAAP Financial Measures” below.

“We see continued improvement in our business. 
Travelzoo is loved by travel enthusiasts who look for quality offers. 
Travelzoo members are affluent, active, and open for new experiences. 75% say 
Travelzoo influences their travel destinations because they trust 
Travelzoo. We believe that trust is becoming an important competitive advantage for Travelzoo,” said  Holger Bartel, Global CEO.

Cash Position
As of 
March 31, 2021, consolidated cash, cash equivalents and restricted cash were 
$72.0 million. Cash flow from operations was 
$11.9 million. There were no significant capital expenditures.

Reserve
Reported revenues include a reserve of 
$4.0 million related to commissions to be earned from vouchers sold. The reserve is booked as contra revenue. For Q1 2021, an adjustment to the reserve reduced reported revenue by 
$56,000.

Travelzoo North America

North America business segment revenue decreased 23% year-over-year to 
$9.8 million. Operating profit for Q1 2021 was 
$39,000, or 0.4% of revenue, compared to an operating loss of 
$976,000 in the prior-year period.

Travelzoo Europe

Europe business segment revenue decreased 48% year-over-year to 
$3.6 million. Operating loss for Q1 2021 was 
$696,000, compared to an operating loss of 
$1.3 million in the prior-year period.

Jack’s Flight Club 
On 
January 13, 2020
Travelzoo acquired 60% of Jack’s 
Flight Club, a membership subscription service. Jack’s 
Flight Club revenue increased 30% year-over-year to 
$887,000. Operating loss for Q1 2021 was 
$110,000, compared to an operating loss of 
$3.0 million in the prior-year period. After consolidation with 
Travelzoo, Jack’s 
Flight Club’s net loss was 
$121,000, with 
$73,000 attributable to 
Travelzoo as a result of recording 
$284,000 of amortization of intangible assets related to the acquisition.

Licensing
In 
June 2020
Travelzoo sold its subsidiary in 
Japan, Travelzoo Japan K.K., to Mr.  Hajime Suzuki. In connection with the sale, 
Travelzoo and Travelzoo Japan K.K. entered into a royalty-bearing licensing agreement for the exclusive use of 
Travelzoo members in 
Japan. In 
August 2020
Travelzoo sold its 
Singapore subsidiary to Mr.  Julian Rembrandt and entered into a royalty-bearing licensing agreement for, among other things, the exclusive use of 
Travelzoo’s members in 
Australia
New Zealand, and 
Singapore. Under the licensing agreements, 
Travelzoo’s existing members in 
Australia
Japan
New Zealand, and 
Singapore will continue to be owned by 
Travelzoo as the licensor. Licensing revenue is booked with a lag of one quarter. Licensing revenue from 
Japan of 
$9,000 generated in Q4 2020 was recognized in Q1 2021.

Members and Subscribers
As of 
March 31, 2021, we had 31.8 million members worldwide. In 
North America, the unduplicated number of 
Travelzoo members was 18.1 million as of 
March 31, 2021, up 7% from 
March 31, 2020. In 
Europe, the unduplicated number of 
Travelzoo members was 8.6 million as of 
March 31, 2021, down 6% from 
March 31, 2020. On 
March 15, 2021
Travelzoo added more than 2 million new members in the 
U.S. in connection with a direct competitor from 
Europe exiting the U.S. market. Jack’s 
Flight Club had 1.6 million subscribers as of 
March 31, 2021, down from 1.7 million subscribers as of 
March 31, 2020.

Discontinued Operations
As announced in a press release on 
March 10, 2020
Travelzoo decided to exit its 
Asia Pacific business which in 2019 reduced EPS by 
$0.60. The 
Asia Pacific business has been classified as discontinued operations since 
March 31, 2020. Prior periods have been reclassified to conform with the current presentation. Certain reclassifications have been made for current and prior periods between the continued operations and the discontinued operations in accordance with 
U.S. GAAP.

Income Taxes
Income tax expense was 
$742,000 in Q1 2021, compared to an income tax benefit of 
$517,000 in the prior-year period.

Non-GAAP Financial Measures
Management calculates non-GAAP operating income when evaluating the financial performance of the business. Travelzoo’s calculation of non-GAAP operating income, also called “non-GAAP operating profit” in this press release and today’s earnings conference call, excludes the following items: impairment of intangibles and goodwill, amortization of intangibles, stock option expenses, and severance-related expenses. This press release includes a table which reconciles GAAP operating income to the calculation of non-GAAP operating income. Non-GAAP operating income is not required by, or presented in accordance with, generally accepted accounting principles in 
the United States of America (“GAAP”). This information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

Looking Ahead
We currently expect for Q2 2021 to report significantly higher revenue and profitability. We see a trend of recovery of our revenue. We have been able to reduce our operating expenses, and we believe we can contain many of the lower costs in the foreseeable future.

Conference Call

Travelzoo will host a conference call to discuss first quarter results today at 
11:00 a.m. ET. Please visit http://ir.travelzoo.com/events-presentations to download the management presentation (PDF format) to be discussed in the conference call; and access the webcast.

About Travelzoo

Travelzoo® provides our 30 million members insider deals and one-of-a-kind experiences personally reviewed by one of our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. For over 20 years we have worked in partnership with more than 5,000 top travel suppliers—our long-standing relationships give 
Travelzoo members access to irresistible deals.

Certain statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. These forward-looking statements may include, but are not limited to, statements about our plans, objectives, expectations, prospects and intentions, markets in which we participate and other statements contained in this press release that are not historical facts. When used in this press release, the words “expect”, “predict”, “project”, “anticipate”, “believe”, “estimate”, “intend”, “plan”, “seek” and similar expressions are generally intended to identify forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including changes in our plans, objectives, expectations, prospects and intentions and other factors discussed in our filings with the 
SEC. We cannot guarantee any future levels of activity, performance or achievements. 
Travelzoo undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Travelzoo, Top 20, and 
Jack’s Flight Club are registered trademarks of 
Travelzoo.

 
Travelzoo
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except per share amounts)
   
  Three months ended
  March 31,
  2021   2020
Revenues $ 14,284     $ 20,327  
Cost of revenues 3,018     2,703  
Gross profit 11,266     17,624  
Operating expenses:      
Sales and marketing 6,790     13,094  
Product development 683     1,428  
General and administrative 4,560     5,522  
Impairment of intangible asset and goodwill     2,920  
Total operating expenses 12,033     22,964  
Operating loss (767 )   (5,340 )
Other income (loss), net (166 )   (6 )
Loss from continuing operations before income taxes (933 )   (5,346 )
Income tax expense (benefit) 742     (517 )
Loss from continuing operations (1,675 )   (4,829 )
Loss from discontinued operations, net of tax (15 )   (2,919 )
Net loss (1,690 )   (7,748 )
Net loss attributable to non-controlling interest (48 )   (1,139 )
Net loss attributable to 
Travelzoo
$ (1,642 )   $ (6,609 )
       
Net loss attributable to Travelzoo—continuing operations $ (1,627 )   $ (3,690 )
Net loss attributable to Travelzoo—discontinued operations $ (15 )   $ (2,919 )
       
Loss per share—basic      
Continuing operations $ (0.14 )   $ (0.32 )
Discontinued operations $     $ (0.26 )
Net loss per share —basic $ (0.14 )   $ (0.58 )
       
Loss per share—diluted      
Continuing operations $ (0.14 )   $ (0.32 )
Discontinued operations $     $ (0.26 )
Net loss per share—diluted $ (0.14 )   $ (0.58 )
Shares used in per share calculation from continuing operations—basic 11,391     11,439  
Shares used in per share calculation from discontinued operations—basic 11,391     11,439  
Shares used in per share calculation from continuing operations—diluted 11,391     11,439  
Shares used in per share calculation from discontinued operations—diluted 11,391     11,439  
           

 

 
Travelzoo
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
       
  March 31,
2021
  March 31,
2020
Assets      
Current assets:      
Cash and cash equivalents $ 70,862     $ 63,061  
Accounts receivable, net 7,293     4,519  
Prepaid income taxes 1,443     931  
Deposits 101     137  
Prepaid expenses and other 3,275     1,166  
Assets from discontinued operations 123     230  
Total current assets 83,097     70,044  
Deposits and other 1,351     745  
Deferred tax assets 4,400     5,067  
Restricted cash 1,157     1,178  
Operating lease right-of-use assets 8,474     8,541  
Property and equipment, net 1,152     1,347  
Intangible assets, net 4,250     4,534  
Goodwill 10,944     10,944  
Total assets $ 114,825     $ 102,400  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accounts payable $ 8,750     $ 6,996  
Merchant payables 70,094     57,104  
Accrued expenses and other 10,827     8,649  
Deferred revenue 2,417     2,688  
Operating lease liabilities 3,796     3,587  
PPP notes payable (current portion) 3,460     2,849  
Income tax payable 201     326  
Liabilities from discontinued operations 580     671  
Total current liabilities 100,124     82,870  
PPP notes payable 204     814  
Deferred tax liabilities 235     357  
Long-term operating lease liabilities 10,558     10,774  
Other long-term liabilities 2,027     1,085  
Total liabilities 113,148     95,900  
Non-controlling interest 4,560     4,609  
Common stock 115     114  
Treasury stock (at cost) (1,583 )    
Additional paid-in capital 4,279     6,239  
Retained earnings (accumulated deficit) (2,045 )   (403 )
Accumulated other comprehensive loss (3,649 )   (4,059 )
Total stockholders’ equity (2,883 )   1,891  
Total liabilities and stockholders’ equity $ 114,825     $ 102,400  
               

 

 
Travelzoo
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
   
  Three months ended
  March 31,
  2021   2020
Cash flows from operating activities:      
Net income (loss) $ (1,690 )   $ (7,748 )
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Depreciation and amortization 484     551  
Stock-based compensation 882     23  
Deferred income tax 541     (609 )
Impairment of intangible assets and goodwill     2,920  
Loss on long-lived assets     437  
Loss on equity investment in WeGo     195  
Net foreign currency effects (152 )   (681 )
Provision of loss on accounts receivable and other (454 )   1,441  
Changes in operating assets and liabilities, net of acquisitions:      
Accounts receivable (2,229 )   2,509  
Income tax receivable (545 )   989  
Prepaid expenses and other (2,357 )   862  
Accounts payable 1,727     547  
Merchant payables 13,212     (6,940 )
Accrued expenses and other 2,199     704  
Income tax payable (126 )   (333 )
Other liabilities 412     2,077  
Net cash provided by operating activities 11,904     (3,056 )
Cash flows from investing activities:      
Acquisition of business, net of cash acquired     (679 )
Purchases of property and equipment (7 )   (131 )
Net cash provided by (used in) investing activities (7 )   (810 )
Cash flows from financing activities:      
Repurchase of common stock (1,583 )   (1,205 )
Payment of promissory notes     (1,000 )
Proceeds from exercise of stock options, net of taxes for net share settlement (2,840 )    
Net cash used in financing activities (4,423 )   (2,205 )
Effect of exchange rate on cash, cash equivalents and restricted cash 270     (272 )
Net increase in cash, cash equivalents and restricted cash 7,744     (6,343 )
Cash, cash equivalents and restricted cash at beginning of period 64,385     20,710  
Cash, cash equivalents and restricted cash at end of period $ 72,129     $ 14,367  
               

 

 
Travelzoo
Segment Information from Continuing Operations
(Unaudited)
(In thousands)
                   
Three months ended
March 31, 2021
Travelzoo
North

America
  Travelzoo
Europe
  Jack’s Flight
Club
  Elimination   Consolidated
Revenue from unaffiliated customers $ 9,828     $ 3,569     $ 887     $     $ 14,284  
Intersegment revenue (9 )   9              
Total net revenues 9,819     3,578     887         14,284  
Operating income (loss) $ 39     $ (696 )   $ (110 )   $     $ (767 )
                   
Three months ended
March 31, 2020
Travelzoo
North

America
  Travelzoo
Europe
  Jack’s Flight
Club
  Elimination   Consolidated
Revenue from unaffiliated customers $ 12,549     $ 7,103     $ 683     $ (8 )   $ 20,327  
Intersegment revenue 148     (156 )       8      
Total net revenues 12,697     6,947     683         20,327  
Operating loss $ (976 )   $ (1,341 )   $ (3,015 )   $ (8 )   $ (5,340 )
                                       

 

 
Travelzoo
Reconciliation of GAAP to Non-GAAP Information
(Unaudited)
(In thousands, except per share amounts)
   
  Three months ended
March 31
  2021   2020
GAAP operating expense $ 12,033     $ 22,964  
Non-GAAP adjustments:      
Impairment of intangible and goodwill (A)     2,920  
Amortization of intangibles (B) 284     215  
Stock option expenses (C) 882     23  
Severance-related expenses (D) 223     217  
Non-GAAP operating expense 10,644     19,589  
       
GAAP operating income (loss) (767 )   (5,340 )
Non-GAAP adjustments (A through D) 1,389     3,375  
Non-GAAP operating income (loss) 622     (1,965 )
       

Investor Relations:
Almira Pusch
[email protected]

 

Source: Travelzoo

Release – Lineage Cell Therapeutics (LCTX) – Announces Appointment Of Dr. Dipti Amin To Its Board Of Directors

 


Lineage Announces Appointment Of Dr. Dipti Amin To Its Board Of Directors

 

Medically Trained Senior Executive/Board Member with Extensive Experience in Clinical Research and Drug Development

CARLSBAD, Calif.–(BUSINESS WIRE)–Apr. 22, 2021– 

Lineage Cell Therapeutics, Inc.
 (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appointment of Dr.  Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM, to the Company’s Board of Directors, effective as of 
April 20, 2021Dr. Amin is an experienced Non-Executive Director and a medically trained senior executive with broad expertise in medicine, pharmacology, healthcare, research, and product development.  Dr. Amin has more than 26 years of experience within the pharmaceutical sector and is accomplished across diverse functional areas including clinical research, drug development, ethics and compliance, and commercial operations. She currently serves as a Non-Executive Director on the board of directors of 

Buckinghamshire Healthcare National Health Service Trust
 and the 
University of Hertfordshire in the 
UK.

“We are honored that  Dr. Amin will be joining Lineage’s Board of Directors at this important time in the advancement of our mission to become the leading allogeneic cell transplant company,” stated  Al Kingsley, Lineage’s Chairman of the Board. “Dr. Amin has had leadership responsibility for many aspects of pharmaceutical product development and clinical trials and has worked with numerous sponsors on countless product candidates while at Quintiles (now IQVIA). We believe her breadth of experience in clinical research and drug development, as well as her medical expertise and practical operational experience, will be particularly valuable to our Board and management team as Lineage continues to advance its three product candidates toward later stage clinical trials. We look forward to her support in guiding our corporate, product, and clinical strategy as we position ourselves for years of growth in the field of cell therapy.”

“Lineage’s clinical-stage programs and platform technologies have the potential to transform outcomes for patients suffering from serious medical conditions,” stated  Dr. Amin. “I am excited about the opportunity to contribute to the Company’s future growth. I particularly look forward to helping guide the advancement of Lineage’s novel cell therapy product candidates toward later-stage clinical trials and the execution of other potentially valuable development activities, with an ultimate focus on transforming the lives of patients and creating value for the Company’s shareholders.”

Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM

Dipti Amin  is an experienced Non-Executive Director and medically trained senior executive with a passion for high quality pharmaceutical research and healthcare, and extensive commercial, leadership, operational experience, in the private & public sectors, in medicine, pharmacology and the highly-regulated healthcare & research sectors, as well as compliance expertise. Over a span of more than 26 years,  Dr. Amin has held positions of operational and strategic responsibility within Pharmaceutical Services at the C-suite and Board level, delivering consistently on growth, quality, customer, employee and process targets. Her broad experience covers Clinical Pharmacology, ethical issues in clinical research, drug development, ethics and compliance programs as well as leadership and management of large, multi-functional, multi-geography, global groups to deliver value-added, efficient growth and achieving business turnarounds.  Dr. Amin has extensive international operational experience, including in the 
U.S.
India
East Asia and 
Africa.

Dr. Amin spent more than 20 years at Quintiles Transnational (now IQVIA), the world’s largest provider of biopharmaceutical development & commercial outsourcing services. During her tenure,  Dr. Amin served in a number of senior executive roles including: Compliance; Ethics & Quality; Drug Safety and Medical Affairs; Medical and Scientific Services; Regulatory Affairs, Medical Writing and Strategic Drug Development; and Clinical Development and Scientific Operations.  Dr. Amin has successfully developed strategy and helped grow the P&L, sales & management for business units generating up to 
$600 million in revenue, while employing internationally based, multi-functional groups of highly qualified personnel.  Dr. Amin is an Honorary Lecturer in Clinical Pharmacology at Guy’s, King’s, and St. Thomas’ Hospitals Medical & Dental Schools.  Dr. Amin has also served on the Boards of 
Cambridge Innovation Capital and the Faculty of Pharmaceutical Medicine of the 
Royal College of Physicians, on the Innovation Board and Medical Expert Network of the 
Association of the British Pharmaceutical Industry, on a 
Department of Health Multi-centre Research Ethics Committee, on the 
Emerging Science and Bioethics Advisory Committee of the Dept. of Health, and on the 
Board of Governors of Heathfield School for Girls (The Girls’ 
Day School Trust).

Dr. Amin received her MB, BS (Bachelor of Medicine; Bachelor of Surgery) from 
Guys Hospital and St Thomas’ Hospitals (now GKT) 
Medical School in 1987. She holds the following certifications: DRCOG (Diploma of the 
Royal College of Obstetrics & Gynaecologists), DGM (Diploma in Geriatric Medicine of the 
Royal College of Physicians), MRCGP (Member of the 
Royal College of General Practitioners), DCH (Diploma in 
Child Health of the 
Royal College of Physicians), DCPSA (Diploma in Clinical Pharmacology), MFPM (Awarded Membership by Distinction of the Faculty of Pharmaceutical Medicine) and FFPM (Fellow of the Faculty of Pharmaceutical Medicine). Her clinical research work has been widely published in professional journals and textbooks, and she is a recognized presenter at international conferences.

About Lineage Cell Therapeutics, Inc. 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Lineage’s clinical advancement of its three product candidates, Lineage’s potential growth in the field of cell therapy, the potential of Lineage’s clinical-stage programs and platform technologies to help patients, and Lineage’s positioning for future success. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks described in Lineage’s filings with the 
Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the 
SEC, including Lineage’s most recent Annual Report on Form 10-K filed with the 
SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
([email protected])
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
([email protected])
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or  David Schull
[email protected]
[email protected]
(212) 845-4242

Source: 
Lineage Cell Therapeutics, Inc.

Release – Ceapro Inc. (CRPOF)(CZO:CA) – Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights


Ceapro Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

 

  • Maintained production operations during COVID-19 pandemic, providing customers with essential products and completing integration of manufacturing sitewhile ensuring the health and safety of employees
  • Substantially increased sales, net profits and cash generated from operations during the year 2020, representing one of Ceapro’s best performances in company history
  • R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19

EDMONTON, Alberta, April 22, 2021 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2020.

“We could not be prouder of our resilient employees who worked tirelessly to deliver one of the best ever performances in the Company’s history during such a stressful year marked by the ongoing COVID-19 pandemic. While ensuring safety of our employees as our first priority, we were able to secure business continuity by putting more emphasis on production operations to serve our customers in the cosmetic sector. This approach, which has resulted in significant increase in sales, net profits and cash on hand, also allowed us to maintain investments in Research and Development as per our strategy to expand Ceapro’s business model from a contract manufacturer/commodity company to a high-value life science/biopharmaceutical company offering innovative products and delivery systems to the healthcare sector,” stated Gilles Gagnon, M.Sc., MBA, President and CEO, of Ceapro.

“In addition to excellent financial and operational results, main highlights of the year include the development of beta glucan from yeast and its potential as an inhalable therapeutic for COVID-19 patients as well as the development of new chemical complexes through the use of the PGX Technology. We are thrilled with the achievements made in 2020,” added Mr. Gagnon.

2020 Corporate and Operational Highlights

Pipeline Development

Oat Beta Glucan:

  • Resumed enrollment of patients for the clinical trial with beta glucan as a cholesterol reducing natural pharmaceutical product. The study will enroll approximately 264 patients. To date, two thirds of the patients have been screened and randomized.

  • Received approval from Health Canada for an amendment to the protocol to allow evaluation of subjects with confirmed pathophysiological condition of hyperlipidemia who voluntarily request to be treated with beta glucan only, without regular dosing of statins. This significant change, allowing patients to receive beta glucan as a stand-alone therapy, has accelerated patient enrollment and is expected to expand the target addressable patient population.

Avenanthramides:

  • Announced the publication of positive results from study evaluating avenanthramides in exercise-induced inflammation in the international, peer-reviewed Journal of the International Society of Sports Nutrition. Positive results support anti-inflammatory claims for avenanthramides as a nutraceutical product and pave the way for a Phase 1 clinical trial as a potential pharmaceutical product.

  • Continued to monitor stability studies for liquid avenanthramides produced at a new manufacturing site as well as for the pharmaceutical-grade dry powder formulation of avenanthramides to be used in a human Phase 1 bioavailability and safety study.

New Products:

Cannabis

  • Received approval from Health Canada Controlled Substances and Cannabis Branch for a five-year research license with medical cannabis for the formulation of unique solid cannabinoid delivery systems using PGX technology.

Yeast Beta Glucan (YBG)

  • Developed an optimal formulation of YBG coming from various sources.

  • Confirmed capability of PGX Technology to optimize and standardize the size and morphology of yeast beta-glucan (PGX-YBG) suitable for lung inhalation.

  • Achieved the first milestones in successful development of PGX-processed yeast beta glucan product as a potential inhalable therapeutic for COVID-19 and other fibrotic endpoint diseases of the lung.

  • Conducted an in-vitro study with human cell lines demonstrating that PGX-YBG obtained from different sources exhibited significant stimulatory effect on human immune response through activation of beta glucan specific Dectin 1 receptors.

  • Ongoing PGX-YBG project with McMaster University conducted in parallel for naïve and preclinical animal models. To date, no safety issues have been encountered. The preclinical phase has been extended to identify the maximum tolerated dose.

  • Conducted additional in vitro PGX-YBG dose response study to correlate with upcoming McMaster animal study results. YBG induces immunomodulation without affecting inflammation pathways. This product is poised to become a key strategic asset for the Company.

New Chemical Complexes:

  • Developed new PGX-dried chemical complexes like sodium alginate and gum arabic impregnated with co-enzyme Q10 (CoQ10). Positive results published in peer-reviewed journals demonstrate the versatility of the PGX Technology and the potential to develop significant bioactive delivery systems. Key learnings from these studies pave the way for the scale-up of the technology at the commercial level.

  • Subsequent to year-end, Ceapro announced the successful completion of a long-term research program conducted with University of Alberta. This screening program allowed Ceapro to retain the most promising products and expand the PGX-based products pipeline.

Technology:

  • Performed significant technical upgrades of PGX pilot plant in Edmonton to allow production of yeast beta glucan for a potential clinical trial with COVID-19 patients.

  • Completed a feasibility study for the commercial scale up of the PGX Technology. Several manufacturers and existing supercritical plants were contacted in 2020 for the choice of equipment and location. Given excellent results obtained with the new yeast beta glucan product, it became clear that location of the first large scale PGX unit should be close to the best source of raw material which was found in Germany where the Company also acquired pieces of equipment suitable for the assembling of such unit. Production at the retained site will be mostly for the commercialization of yeast beta glucan as an immune booster and for alginate as a carrier for other bioactives.

  • Initiated installment in Edmonton of a commercial scale unit for impregnation of bioactives with PGX-processed biopolymers.

  • Pursued research collaboration projects with University of Alberta and McMaster University for the impregnation of various bioactives using PGX-processed biopolymers as potential delivery systems for multiple applications in healthcare.

Bioprocessing Operations

  • Completed the integration of production operations under one roof in Edmonton. Ceapro’s dedicated production team successfully responded to the growing market demand for the cosmeceutical base business by producing over 250 metric tons of active ingredients in 2020, a 25% increase over the previous year.

  • Received renewal of the Site License from the Health Canada Natural Product Directorate. This License enables the Company to manufacture, package, label, release and distribute final products.

Corporate

  • Fully repaid loan with Agriculture Financial Services Corporation.

  • Announced expansion of a grant from National Research Council of Canada for the optimization and mass production of yeast beta glucan as a potential inhalable therapeutic for COVID-19 and other fibrotic end-point disease of the lung.

  • Pursued out-licensing discussions for PGX-processed new chemical complexes.

  • Secured DTC Eligibility for publicly traded shares under Ticker OTCQZ: CRPOF and to expand Company exposure to other markets with an emphasis in USA.

Financial Highlights for the Fourth Quarter and the Full Year 2020 Ended December 31, 2020

  • Total sales of $2,706,000 for the fourth quarter of 2020 and $15,121,000 for the full year of 2020 compared to $3,721,000 and $12,880,000 for the comparative periods in 2019. The 17% increase in revenue for the full year 2020 results from an 33% increase in sales of avenanthramides (mostly made to USA) partially offset by a 16% decrease in sales of beta glucan.

  • Net loss of $539,000 for the fourth quarter of 2020 and a net profit of $1,856,000 for the full year of 2020 compared to a net profit of $166,000 and a net loss of $1,133,000 for the comparative periods in 2019, a year over year improvement of $2,989,000 Third and fourth quarter 2020 were marked by the completion of the decommissioning of Leduc manufacturing site and the final integration of production operations in the Edmonton facility. These time-consuming moves resulted in some necessary adjustments in equipment at the new site. It also required additional training of relocated employees.

  • Cash generated from operations of $4,453,000, for the full year 2020 vs cash generated from operations of $882,000 for the full year 2019.

  • Positive working capital balance of $7,659,000 as of December 31, 2020.

“I strongly believe 2021 holds a lot of opportunity for Ceapro. Our focus remains on the health and safety of our associates during this COVID-19 pandemic crisis, followed by business continuity. Depending on the evolution of the COVID-19 pandemic, we expect Ceapro’s cosmeceuticals base business to continue to grow and provide positive operating cash flows to support the expansion to a new business model from a contract manufacturer to a biopharmaceutical development company involved in nutraceuticals and pharmaceuticals. Based on a very solid foundation, a highly competent team, a healthy balance sheet and a very strong technology and product portfolio with the potential to access key large markets, we have all the key components for success,” concluded Mr. Gagnon.

CEAPRO INC.    
Consolidated Balance Sheets    
     
  December 31, December 31,
  2020 2019
  $ $
     
ASSETS    
Current Assets    
Cash and cash equivalents 5,369,029 1,857,195
Trade receivables 2,019,723 3,659,541
Other receivables 102,224 46,812
Inventories (note 3) 1,210,079 669,005
Prepaid expenses and deposits 348,845 178,908
     
  9,049,900 6,411,461
Non-Current Assets    
   Investment tax credits receivable 607,700 607,700
Deposits 82,124 85,755
Licences (note 4) 18,514 21,477
Property and equipment (note 5) 18,591,189 19,764,122
Deferred tax assets (note 14 (b)) 874,304 378,643
     
  20,173,831 20,857,697
     
TOTAL ASSETS 29,223,731 27,269,158
     
LIABILITIES AND EQUITY    
Current Liabilities    
Accounts payable and accrued liabilities 1,067,622 1,291,204
Current portion of long-term debt (note 6) 111,865
Current portion of lease liabilities (note 7) 250,658 265,123
Current portion of CAAP loan (note 9) 72,263 72,942
     
  1,390,543 1,741,134
Non-Current Liabilities    
Long-term lease liabilities (note 7) 2,648,917 2,775,627
CAAP loan (note 9) 61,580
Deferred tax liabilities (note 14 (b)) 874,304 378,643
     
  3,523,221 3,215,850
     
TOTAL LIABILITIES 4,913,764 4,956,984
     
Equity    
Share capital (note 8 (b)) 16,511,067 16,401,677
Contributed surplus (note 8 (e)) 4,682,393 4,650,090
Retained earnings 3,116,507 1,260,407
     
  24,309,967 22,312,174
     
TOTAL LIABILITIES AND EQUITY 29,223,731 27,269,158
     


CEAPRO INC.    
Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
     
   
  2020   2019  
Year Ended December 31, $ $
     
Revenue (note 16) 15,121,282   12,880,006  
Cost of goods sold 7,498,996   7,434,654  
     
Gross margin 7,622,286   5,445,352  
     
Research and product development 1,881,883   2,393,607  
General and administration 3,282,754   2,952,488  
Sales and marketing 111,044   425,230  
Finance costs (note 12) 231,271   260,684  
     
Income (loss) from operations 2,115,334   (586,657 )
     
Other expenses (note 11) (259,234 ) (549,379 )
     
Income (loss) before tax 1,856,100   (1,136,036 )
     
Income taxes    
   Current tax recovery    
   Deferred tax benefit   3,408  
     
Income tax benefit   3,408  
     
Total comprehensive income (loss) for the year 1,856,100   (1,132,628 )
     
Net income (loss) per common share (note 21):    
Basic 0.02   (0.01 )
Diluted 0.02   (0.01 )
     
Weighted average number of common shares outstanding (note 21):    
Basic 77,594,629   77,188,505  
Diluted 78,143,033   77,188,505  
     


CEAPRO INC.    
Consolidated Statements of Cash Flows    
     
     
  2020   2019  
Year Ended December 31, $ $
OPERATING ACTIVITIES    
Net income (loss) for the year 1,856,100   (1,132,628 )
Adjustments for items not involving cash    
Finance costs 153,538   171,249  
Transaction costs 1,108   4,187  
Depreciation and amortization 1,841,033   1,831,744  
Foreign exchange gain on long-term debt   (307 )
Accretion 21,625   30,248  
Deferred tax benefit   (3,408 )
Share-based payments 136,796   212,517  
Net income (loss) for the year adjusted for non-cash items 4,010,200   1,113,602  
CHANGES IN NON-CASH WORKING CAPITAL ITEMS    
Trade receivables 1,639,818   (644,197 )
Other receivables (55,412 ) 87  
Inventories (541,074 ) 41,703  
Prepaid expenses and deposits (88,839 ) 154,106  
Accounts payable and accrued liabilities relating to operating activities (358,136 ) 388,064  
Total changes in non-cash working capital items 596,357   (60,237 )
Net income (loss) for the year adjusted for non-cash and working capital items 4,606,557   1,053,365  
Interest paid (153,538 ) (171,249 )
CASH GENERATED FROM OPERATIONS 4,453,019   882,116  
INVESTING ACTIVITIES    
Purchase of property and equipment (528,707 ) (332,186 )
Purchase of leasehold improvements (12,870 ) (6,007 )
Proceeds from sale of equipment 353    
Deposits relating to investment in equipment (77,467 ) 187,790  
Accounts payable and accrued liabilities relating to investing activities 134,554   (46,738 )
CASH USED IN INVESTING ACTIVITIES (484,137 ) (197,141 )
FINANCING ACTIVITIES    
Stock options exercised 4,897   17,284  
Repayment of long-term debt (112,973 ) (339,321 )
Repayment of CAAP loan (83,884 ) (83,884 )
Repayment of lease liabilities (265,088 ) (265,993 )
CASH USED IN FINANCING ACTIVITIES (457,048 ) (671,914 )
Increase in cash and cash equivalents 3,511,834   13,061  
     
Cash and cash equivalents at beginning of the year 1,857,195   1,844,134  
     
Cash and cash equivalents at end of the year 5,369,029   1,857,195  
     

The complete financial statements are available for review on SEDAR at https://sedar.com/Ceapro and on the Company’s website at www.ceapro.com.


About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: [email protected]

Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release



Source: Ceapro Inc.

Release – Sierra Metals Inc. (SMT:CA)(SMTS) – To Invest US$28 Million For An Iron Ore Processing Plant


Sierra Metals To Invest US$28 Million For An Iron Ore Processing Plant Expected To Produce Approximately 500,000 Tonnes Per Year Of Magnetite Concentrate At The Bolivar Mine, Mexico

 

TORONTO–(BUSINESS WIRE)– Sierra Metals Inc. (TSX: SMT) (BVL: SMT) (NYSE AMERICAN: SMTS) (“Sierra Metals” or “the Company”) today announces that its Board of Directors has approved the investment by the Company of US$28 million for the construction of a magnetite processing plant including an initial expenditure of $5.2 million for early procurement and contracting on the project. The plant is expected to produce approximately 500,000 tonnes per year of 62% iron ore fines concentrate at the Company’s Bolivar Mine located in the Chihuahua State, Mexico.

Engineering and test work of the final process is currently underway, and construction of the processing plant is expected to commence this June and will take approximately six months to complete. The Company expects to concentrate magnetite as an additional process to the existing copper concentrator plant through a series of magnetic drums and regrinding equipment, at an added marginal cost for the process.

The magnetite project was previously mentioned in the Bolivar Mine’s Preliminary Economic Assessment (the “Report”) which was filed on SEDAR (sedar.com) and EDGAR (SEC.gov) on November 5, 2020. In the Report the Company mentioned that the economic analysis did not include the potential sale of magnetite but that the Company was studying this potential development and believed that doing so could result in the following outcomes:

1. Increased sales revenue

2. Reduced future closure costs; and

3. Reduced tailings for deposition, and its related costs.

The project has now been approved and will be included in an updated PEA for the Bolivar Mine which will be filed within 45 days.

Luis Marchese, CEO of Sierra Metals commented: “We are very excited about initiating this new process the potential for additional revenue for the Company. The iron ore market is presenting value enhancing opportunities for Sierra Metals and the Company is taking decisive action to extract value from its existing iron ore-copper mineral resources. As well, this process is expected to have additional benefits including reduced haulage costs of our copper concentrate by rail and enhance the Bolivar mine’s economics due to this new revenue stream. Overall, we believe that this is a great value-enhancing initiative for the Company and its shareholders.”

Quality Control

Américo Zuzunaga, FAusIMM CP (Mining Engineer) and Vice President of Corporate Planning, is a Qualified Person under National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

Augusto Chung, FAusIMM CP (Metallurgist) and Vice President of Metallurgy and Projects, is a Qualified Person under National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About Sierra Metals

Sierra Metals Inc. is a diversified Canadian mining company focused on the production and development of precious and base metals from its polymetallic Yauricocha Mine in Peru and Bolivar and Cusi Mines in Mexico. The Company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new key discoveries and still has many more exciting brownfield exploration opportunities at all three Mines in Peru and Mexico that are within close proximity to the existing mines. Additionally, the Company also has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential.

The Company’s Common Shares trade on the Bolsa de Valores de Lima and on the Toronto Stock Exchange under the symbol “SMT” and on the NYSE American Exchange under the symbol “SMTS”.

For further information regarding Sierra Metals, please visit www.sierrametals.com

Continue to Follow, Like and Watch our progress:

Webwww.sierrametals.com | Twittersierrametals | FacebookSierraMetalsInc | LinkedInSierra Metals Inc | Instagramsierrametals

Disclaimer Regarding Risks and Forward-Looking Statements

The decision to construct the processing plant has not been made based on a feasibility study and accordingly, involves increased uncertainty and risks.

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of Canadian and U.S. securities laws (collectively, “forward-looking information”). Forward-looking information includes, but is not limited to, statements with respect to the timing of construction of the processing plant, its capacity and production, construction costs and expected iron content of the concentrate. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “assumes”, “intends”, “strategy”, “goals”, “objectives”, “potential” or variations thereof, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking information.

Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated March 30, 2021 for its fiscal year ended December 31, 2020 and other risks identified in the Company’s filings with Canadian securities regulators and the United States Securities and Exchange Commission, which filings are available at www.sedar.com and www.sec.gov, respectively.

The risk factors referred to above are not an exhaustive list of the factors that may affect any of the Company’s forward-looking information. Forward-looking information includes statements about the future and is inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations, and opinions of management on the date the statements are made, and the Company does not assume any obligation to update such forward-looking information if circumstances or management’s beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

Mike McAllister
Vice President, Investor Relations
Sierra Metals Inc.
(416) 366 7777
Email: [email protected]

Luis Marchese
CEO
Sierra Metals Inc.
(416) 366 7777

Source: Sierra Metals Inc.

CO2 Emissions by Country


CO2 Emissions by Country

 

Each Country’s Share of Emissions (GT=Gigaton)

 

Countries across the globe have varying populations and are at different stages of development which influences their CO2 output along with emitting other greenhouse gases into the atmosphere. The International Energy Agency has compiled related data in the pie chart above and tables below. The amount per country and amount per capita are startling in their differences.

 

The 21 Countries that Emitted the Most Carbon Dioxide  

 

 

Measured in gigatons, the top CO2-producing countries are among the most populous and industrial (above). Looking at how much CO2 is released per capita and the list provides a very different perspective. India moves down from #3 to #21, and Kazakstan which was #21 moves up to #2.

 

 

The story that emerges from this data is that, in general, developed countries and major emerging economy nations contribute the most in total carbon dioxide emissions while some developing nations lead in the average emitted carbon dioxide per resident.

 

Sources:

http://energyatlas.iea.org/#!/tellmap/1378539487

https://www.ucsusa.org/resources/each-countrys-share-co2-emissions

 

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Energy Fuels (UUUU)(EFR:CA) – Energy Fuels Signs New Supply Agreement to Process Rare Earth Elements

Thursday, April 22, 2021

Energy Fuels (UUUU)(EFR:CA)
Energy Fuels Signs New Supply Agreement to Process Rare Earth Elements

As of April 24, 2020, Noble Capital Markets research on Energy Fuels is published under ticker symbols (UUUU and EFR:CA). The price target is in USD and based on ticker symbol UUUU. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Energy Fuels is the largest uranium producer in the U.S. and holds more production capacity and uranium resources than any other U.S. producer. The Company also produces vanadium. Headquartered in Colorado, Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch ISR Facility in Wyoming, and the Alta Mesa ISR Facility in Texas. The producing White Mesa Mill is the only conventional uranium mill in the U.S. and has a licensed capacity of 8 million pounds of U3O8 per year. Nichols Ranch is in production and has a licensed capacity of 2 million pounds of U3O8 per year. Alta Mesa is currently on standby. Energy Fuels also owns several licensed and developed uranium and vanadium mines on standby and other projects in development.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Energy Fuels signed an memorandum of understanding with Hyperion Metals to process monazite sand from Hyperion’s Titan Project in Tennessee. The MOU does not specify the quantity of monazite to be processed, but we suspect the arrangement to be similar to Energy Fuels’ agreement with Chemours to process 2,500 tons/year by 2022. Further details will become available after Hyperion completes a mineral reserve estimate and other test work later in the year. Hyperion has released results from initial wells of a drilling program that confirm high concentrations of monazite, as well as titanium, zircon and silica.

    Energy Fuels indicates its intent to ramp up monazite processing at its White Mesa Mill to 15,000 tons/year or greater.  The announcement implies that management expects operations to grow rapidly and that future supply intake agreements could be announced. In addition to growing monazite processing, management has expressed an interest in separating rare earth elements (REE) removed from the …



Energy Fuels CEO Mark Chalmers recently sat down with Noble Capital Markets Senior Research Analyst Michael Heim for an exclusive interview. Topics included current projects, pricing, uranium reserves, supply and demand, vanadium, rare earths, and more.

Watch The ChannelCast Video Now

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Genco Shipping & Trading Limited (GNK) – New 2022 Dividend Estimate and Fleet Renewal Intact

Thursday, April 22, 2021

Genco Shipping & Trading Limited (GNK)
New 2022 Dividend Estimate and Fleet Renewal Intact

Genco Shipping & Trading Limited, incorporated on September 27, 2004, transports iron ore, coal, grain, steel products and other drybulk cargoes along shipping routes through the ownership and operation of drybulk carrier vessels. The Company is engaged in the ocean transportation of drybulk cargoes around the world through the ownership and operation of drybulk carrier vessels. As of December 31, 2016, its fleet consisted of 61 drybulk carriers, including 13 Capesize, six Panamax, four Ultramax, 21 Supramax, two Handymax and 15 Handysize drybulk carriers, with an aggregate carrying capacity of approximately 4,735,000 deadweight tons (dwt). Of the vessels in its fleet, 15 are on spot market-related time charters, and 27 are on fixed-rate time charter contracts. As of December 31, 2016, additionally, 19 of the vessels in its fleet were operating in vessel pools.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Variable dividend policy begins in 1Q2022 and scenarios look attractive.  Our quarterly dividend calculation is based on estimated operating cash flow minus debt amortization, capex for drydocks and a reserve based on future quarterly debt amortization and interest expense.

    Our FY2022 dividend estimate is $2.25/share is based on our 2022 EBITDA estimate of $171.3 million, which implies a current yield of 16.4%.  Assuming TCE rates of $18.8k/day and TCE revenue of $272 million, operating cash flow should approximate $164 million. Incorporating debt amortization of $24 million, drydock capex of $11 million, and a reserve of $34 million, net cash flow of $95 million …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.